Compare CPSS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | PBYI |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 263.4M |
| IPO Year | 1992 | N/A |
| Metric | CPSS | PBYI |
|---|---|---|
| Price | $9.38 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 22.6K | ★ 389.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 0.80 | 0.74 |
| Revenue | $196,531,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $139.62 | N/A |
| Revenue Next Year | $10.58 | N/A |
| P/E Ratio | $11.59 | ★ $7.80 |
| Revenue Growth | ★ 6.67 | N/A |
| 52 Week Low | $6.67 | $2.58 |
| 52 Week High | $12.73 | $6.12 |
| Indicator | CPSS | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 67.11 |
| Support Level | $8.39 | $4.84 |
| Resistance Level | $8.74 | $5.11 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 80.69 | 99.01 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.